Efficacy and safety of camrelizumab-based comprehensive treatment for non-small cell lung cancer: a systematic review and meta-analysis

Abstract

Background: Many studies show that camrelizumab combination therapy can significantly improve progression-free survival (PFS) and overall survival (OS) in non-small cell lung cancer (NSCLC). However, the time of camrelizumab to market is short, and there is no systematic evaluation of camrelizumab-based comprehensive treatment of NSCLC. Objectives: To systematically evaluate the efficacy and safety of camrelizumab in comprehensively treating NSCLC. Design: A systematic review and meta-analysis. Data sources and methods: Databases, including PubMed, Web of Science, Embase, and Cochrane, were searched by computer before August 2023 based on Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines, and reports on the efficacy and safety of camrelizumab-based treatment for NSCLC were collected, and RevMan 5.4 software was employed for meta-analysis finally. Results: Totally, 5 RCTs, 2 cohort studies, and 12 single-arm studies were included. The meta-analysis results revealed that, compared with the treatment without camrelizumab, the camrelizumab-based combination treatment considerably extended the OS (hazard ratio (HR) = 0.60, 95% confidence interval (CI): (0.44–0.82), p < 0.01), PFS (HR = 0.42, 95% CI: (0.28–0.63), p < 0.01), and event-free survival (EFS) (HR = 0.55, 95% CI: (0.44–0.68), p < 0.01). The median objective response rate in single-arm studies was 41% (95% CI: 28%–53%), and the disease control rate was 84% (95% CI: 78%–89%). Furthermore, in terms of the occurrence of grades 3–5 adverse events, the incidence of neutropenia was lower in the camrelizumab combination group than in the control group, while the incidence of leukopenia and rash was higher than in the combination group, and no significant difference was revealed in the incidence of other adverse events. Among single-arm studies, the incidence of grades 3–5 adverse events did not exceed 10%. Conclusion: Treatment combined with camrelizumab can effectively prolong OS, PFS, and EFS in NSCLC patients with good safety, camrelizumab combined with chemotherapy is an effective treatment option for NSCLC patients.